Literature DB >> 7695281

Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.

G A Pankuch1, M R Jacobs, P C Appelbaum.   

Abstract

MICs of eight beta-lactams (piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone) were determined by agar dilution against 64 penicillin-susceptible, 70 intermediately penicillin-resistant, and 66 fully penicillin-resistant pneumococci. The MICs of piperacillin with and without tazobactam for 90% of the susceptible, intermediately resistant, and resistant strains tested (MIC90s) were < or = 0.064, 2.0, and 4.0 micrograms/ml, respectively. By comparison, those of ampicillin with and without sulbactam were 0.125, 2.0, and 4.0 micrograms/ml and those of ceftriaxone were < or = 0.064, 1.0, and 2.0 micrograms/ml, respectively. Strains were less susceptible to ticarcillin with and without clavulanate (MIC90s, 2.0, 64.0, and 128.0 micrograms/ml) and ceftazidime (MIC90s, 1.0, 8.0, and 32.0 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7695281      PMCID: PMC188305          DOI: 10.1128/AAC.38.12.2905

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone.

Authors:  A M Figueiredo; J D Connor; A Severin; M V Vaz Pato; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 2.  Management of penicillin-resistant pneumococcal infections.

Authors:  I R Friedland; G R Istre
Journal:  Pediatr Infect Dis J       Date:  1992-06       Impact factor: 2.129

Review 3.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

Authors:  J Liñares; R Pallares; T Alonso; J L Perez; J Ayats; F Gudiol; P F Viladrich; R Martin
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

5.  Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics.

Authors:  J S Bradley; J D Connor
Journal:  Pediatr Infect Dis J       Date:  1991-11       Impact factor: 2.129

6.  Antibiotic-resistant pneumococcal disease in South African children.

Authors:  I R Friedland; K P Klugman
Journal:  Am J Dis Child       Date:  1992-08

Review 7.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

8.  Penicillin-binding proteins of penicillin-susceptible and -resistant pneumococci: immunological relatedness of altered proteins and changes in peptides carrying the beta-lactam binding site.

Authors:  R Hakenbeck; H Ellerbrok; T Briese; S Handwerger; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

9.  Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin.

Authors:  J I Ward; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

Review 10.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

View more
  6 in total

1.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

Review 2.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

3.  Antimicrobial susceptibilities and serotypes of invasive Streptococcus pneumoniae strains in Switzerland.

Authors:  J Wüst; E Huf; F H Kayser
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

4.  Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.

Authors:  K S Thomson; S A Chartrand; C C Sanders; S L Block
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 5.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

6.  Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.